Conduit Pharmaceuticals (CDT) Competitors $0.09 0.00 (-1.37%) (As of 05:20 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends CDT vs. RLYB, PASG, CLNN, OKYO, CALC, NXTC, LTRN, LEXX, BLRX, and LUMOShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include Rallybio (RLYB), Passage Bio (PASG), Clene (CLNN), OKYO Pharma (OKYO), CalciMedica (CALC), NextCure (NXTC), Lantern Pharma (LTRN), Lexaria Bioscience (LEXX), BioLineRx (BLRX), and Lumos Pharma (LUMO). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. Rallybio Passage Bio Clene OKYO Pharma CalciMedica NextCure Lantern Pharma Lexaria Bioscience BioLineRx Lumos Pharma Conduit Pharmaceuticals (NASDAQ:CDT) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Do analysts prefer CDT or RLYB? Rallybio has a consensus target price of $9.75, indicating a potential upside of 865.35%. Given Rallybio's higher probable upside, analysts clearly believe Rallybio is more favorable than Conduit Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community favor CDT or RLYB? Rallybio received 38 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Conduit Pharmaceuticals an outperform vote while only 76.47% of users gave Rallybio an outperform vote. CompanyUnderperformOutperformConduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesRallybioOutperform Votes3976.47% Underperform Votes1223.53% Do institutionals & insiders hold more shares of CDT or RLYB? 3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 34.7% of Conduit Pharmaceuticals shares are owned by insiders. Comparatively, 7.4% of Rallybio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher valuation and earnings, CDT or RLYB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConduit PharmaceuticalsN/AN/A-$540KN/AN/ARallybioN/AN/A-$74.56M-$1.60-0.63 Which has more risk & volatility, CDT or RLYB? Conduit Pharmaceuticals has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.67, indicating that its stock price is 267% less volatile than the S&P 500. Does the media favor CDT or RLYB? In the previous week, Rallybio had 4 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 6 mentions for Rallybio and 2 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 0.72 beat Rallybio's score of 0.65 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Conduit Pharmaceuticals Positive Rallybio Positive Is CDT or RLYB more profitable? Conduit Pharmaceuticals' return on equity of 0.00% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets Conduit PharmaceuticalsN/A N/A -82.90% Rallybio N/A -77.39%-69.33% SummaryConduit Pharmaceuticals beats Rallybio on 8 of the 14 factors compared between the two stocks. Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.01M$7.02B$5.35B$8.88BDividend YieldN/A8.03%4.98%4.04%P/E RatioN/A11.36132.0617.45Price / SalesN/A376.471,259.5098.78Price / CashN/A49.2239.0436.42Price / Book-9.399.076.265.86Net Income-$540,000.00$153.49M$118.56M$224.86M7 Day PerformanceN/A-2.21%-2.16%-0.94%1 Month PerformanceN/A7.48%2.44%3.65%1 Year PerformanceN/A37.84%35.47%26.39% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit PharmaceuticalsN/A$0.09-1.4%N/A-91.9%$9.01MN/A0.003Upcoming EarningsShort Interest ↓RLYBRallybio3.3618 of 5 stars$0.99-1.0%N/A-57.1%$41.07M$299,000.00-0.5540PASGPassage Bio3.6388 of 5 stars$0.65flatN/A-3.0%$40.23MN/A-0.48130Analyst ForecastPositive NewsGap UpCLNNClene3.1869 of 5 stars$5.89+3.0%N/A-48.6%$39.22M$650,000.00-1.32100Upcoming EarningsAnalyst ForecastShort Interest ↑News CoverageOKYOOKYO Pharma2.6616 of 5 stars$1.13+0.9%N/A-34.9%$37.90MN/A0.007Short Interest ↑CALCCalciMedica3.1145 of 5 stars$3.50flatN/A+0.6%$37.63MN/A-2.5030Analyst ForecastShort Interest ↑News CoverageHigh Trading VolumeNXTCNextCure4.552 of 5 stars$1.32+1.5%N/A+25.9%$36.93MN/A-0.6090Analyst ForecastGap DownLTRNLantern Pharma0.8901 of 5 stars$3.42+3.3%N/A-6.4%$36.82MN/A-2.0720Analyst RevisionLEXXLexaria Bioscience2.3261 of 5 stars$2.32+5.9%N/A+71.2%$36.70M$411,019.00-5.277Upcoming EarningsNews CoverageBLRXBioLineRx2.3088 of 5 stars$0.45flatN/A-67.8%$36.21M$17.05M-1.0040Upcoming EarningsShort Interest ↑News CoverageLUMOLumos Pharma3.0146 of 5 stars$4.33+0.5%N/A+38.7%$35.14M$1.49M-0.9830Short Interest ↓ Related Companies and Tools Related Companies Rallybio Alternatives Passage Bio Alternatives Clene Alternatives OKYO Pharma Alternatives CalciMedica Alternatives NextCure Alternatives Lantern Pharma Alternatives Lexaria Bioscience Alternatives BioLineRx Alternatives Lumos Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDT) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDT Stock Alerts